![A comparison of ATN1, RERE and Atro, and their functional domains.\
The boundaries and the percentage of identical/similar residues within the conserved regions between human ATN1 (Atrophin-1), human RERE (arginine glutamic acid dipeptide repeats protein), and *Drosophila* Atro (Atrophin) are shown. The functional domains, including BAH (bromo adjacent homology), ELM2 (EGL-27 and MTA1 homology 2), SANT (SWI3/ADA2/N-CoR/TFIII-B), RE-repeat (arginine-glutamic acid dipeptide-repeat), ZnF-GATA, and glutamine (Q)-repeat are highlighted in different colors. The mapped nuclear receptor interacting domains at the C-terminus of each protein are marked in dark blue, within which the Atro-box is labeled as a white bar. The ELM2 domain and SANT domain are docking sites where HDAC1/2 (histone deacetylase 1, 2) and G9a (H3-K9 histone methyltransferase) bind, respectively.](nrs06009.f1){#fig1}

![A model depicting the actions of Atrophin-protein complex on chromosomes, signaling pathways, and biological and disease processes.\
Atrophin proteins, such as RERE and Atro, use their ELM2 and SANT domains to recruit HDAC1/2, G9a, and additional chromatin-modifying factors (marked as X, Y, and Z). The coordinated actions of these chromatin-modifying factors enable Atrophin proteins to promote methylation of histone H3-K9 (a hallmark of repression) and change local chromatin structures where Atrophin-associated transcriptional factors (TF) bind. Each Atrophin-associated chromatin-modifying factor represents a target that can be modified by EGFR (epidermal growth factor receptor) signaling and that can be used for screening chemical compounds/drugs for treating DRPLA (dentatorubral-pallidolusian atrophy) or AML1(acute myeloid leukemia 1).](nrs06009.f2){#fig2}

![A comparison of the known properties of SMRT- and Atrophin- proteins.\
The well characterized SMRT class of corepressors, including SMRT (silencing mediator of retinoid and thyroid hormone receptors), N-CoR (nuclear receptor corepressor), and their *Drosophila* cognate SMRTER (SMRT-related ecdysone receptor interacting factor), preferentially bind members of subgroup 1 of the nuclear receptor superfamily, such as TR (thyroid hormone receptor), RAR (retinoic acid receptor), or EcR (ecdysone receptor), and recruits HDAC3. The newly-identified Atrophin class of corepressors, including RERE, ATN1, and their *Drosophila* cognate Atro, in contrast, selectively bind members of the subgroup 2 of nuclear receptors, such as Tll and Tlx, and recruits HDAC1/2. (Note: Rpd3 is the fly HDAC1/2). Whereas Atrophin proteins, except for ATN1, bind G9a both in mammalian cells and in fly, none of the members of the SMRT family proteins have so far been shown to bind HMTases. RXR (retinoid-X receptor) and USP (Ultraspiracle, the fly RXR), are the common binding partners of RAR and TR, and EcR, respectively.](nrs06009.f3){#fig3}

Introduction
============

Atrophin proteins are conserved transcriptional corepressors that, as we recently demonstrated, are involved in nuclear receptor signaling. This review article provides an overview of our current understanding of this new class of nuclear receptor corepressors, which includes vertebrate Atrophin-1 (ATN1), vertebrate arginine glutamic acid repeats encoded protein (RERE), and *Drosophila* Atrophin (Atro).

This review discusses the identification of atrophin proteins, their expression and cellular patterns, their connections with nuclear receptor and epidermal growth factor signaling pathways, functional domains, associations with histone modifying factors, roles in animal development, and their implications in human diseases. Deepening our understanding of the Atrophin proteins will expand our insights about how these nuclear receptor corepressors help transcriptional factors, such as nuclear receptors, regulate gene transcription, exert biological effects, and cause diseases.

The identification of atrophin proteins
=======================================

The *Atn1* gene was initially cloned by Christopher Ross's group at Johns Hopkins University as CTG-B37 in their screens for human genes containing CTG/CAG or CCG/CGG triplet repeats \[[@r49]\]. In 1994, the *Atn1* gene was assigned to the short arm of chromosome 12 and was simultaneously reported by Masao Yamada (National Children's Medical Research Center, Japan) and Shoji Tsuji (Niigata University, Japan) to be a causative factor for the neurodegenerative disease DRPLA (dentatorubral-pallidoluysian atrophy) when the CAG repeat within the coding region of the *Atn1* gene is expanded \[[@r43]; [@r61]\]. In addition to the glutamine-repeat (coded by the CAG repeat), ATN1 also contains two arginine-glutamic acid dipeptide-like repeats (RE-repeats) that reside at its C-terminus. In search of potential ATN1 homologues, Masao Yamada's group identified RERE \[[@r112]\], named after the RE-like repeats present at the C-terminus of the protein. Owing to its resemblance with ATN1, RERE has also been referred to as Atrophin-2.

In 2002, *Drosophila* Atro was reported by two groups independently: Tian Xu's group at Yale University, using a dominant female sterile-FRT/FLP approach, identified *Atro* during their search for lethal mutations that affect growth and patterning \[[@r119]\]; and Steve Kerridge and Laurent Fansano's group at the IBDML (Marseille, France), isolated *Atro* through an EMS mutagenesis in their screening for mutations that affect the expression of the region-specific pattern gene *teashirt* \[[@r21]\]. In the latter study, Atro was also referred to as Grunge. Drawing on their characterization of *Atro* mutants, both groups reported that *Atro* is an essential gene involved in multiple developmental pathways.

Spatial and cellular patterns
=============================

Northern blot analysis reveals that *Atn1* transcripts are ubiquitously expressed in a variety of neuronal and non-neuronal tissues, including brain, heart, lung, kidney, placenta, skeletal muscle and liver \[[@r38]; [@r69]\]. At the cellular level, ATN1 is predominantly localized to the cytoplasm of neuronal cells \[[@r42]\], although in cultured HeLa cells, transiently expressed ATN1 was found to be present within the nucleus \[[@r67]; [@r112]\].

The *Rere* gene codes for two transcripts with estimated sizes of 7.4 and 9.4 kb. Their expression varies considerably in different tissues, being particularly abundant in the cerebellum, testis, uterus, prostate, skeletal muscle and kidney, and relatively lower in lung, colon and leukocytes \[[@r102]; [@r112]\]. The cellular localization of RERE protein was reported based on transient overexpression conditions. In transfected HeLa cells, although a low level of RERE can be detected in the cytoplasm, RERE localizes predominantly to the nucleus, where it forms a speckle-like pattern resembling that of promyelocytic leukemia bodies \[[@r102]; [@r112]\].

In *Drosophila*, Atro is at first ubiquitously distributed throughout the embryo during the early stage \[[@r21]; [@r119]\]. During later stages of embryogenesis, a higher level of Atro becomes more apparent at the ventral nerve cord region. At the third instar larvae stage, Atro resumes its ubiquitously expressed pattern in various examined imaginal tissues. Throughout different developmental stages, Atro mainly localizes to the nucleus of cells, within which endogenous Atro forms a speckle-like pattern \[[@r119]\] . When overexpressed in human cells, consistently, Atro also forms a nuclear speckle pattern \[[@r104]; [@r105]\], indicating that formation of a nuclear speckle pattern is a shared property of Atro and RERE. Interestingly, this unique cellular feature does not apply to ATN1, probably because it lacks the SANT (SWI3/ADA2/N-CoR/TFIII-B) domain (more information about this domain will be provided below), which is essential for RERE to form nuclear foci \[[@r105]\].

Roles of atrophin proteins in animal and *Drosophila* development
=================================================================

A recent study shows that *Atn1* is not an essential gene during mouse development, because *Atn1* knockout mouse is indistinguishable from wild-type mouse \[[@r85]\]. In contrast, *Rere* is required for both mouse and zebrafish to develop and to survive \[[@r4]; [@r76]; [@r123]\]. In mouse, mutations of *Rere* cause a failure in closing the anterior neural tube and fusion of the telencephalic and optic vesicles during early embryogenesis \[[@r123]\]. Other defects include a smaller first branchial arch with a deficit in the mesenchymal component, a fail-to-loop heart tube and somites with irregular shapes and sizes. All homozygous mice die shortly after E9.5, possibly owing to cardiac failure. Accompanying most of these described phenotypes is the disruption of important signaling centers, including the loss of *sonic hedgehog* in the anterior notochord, and defective expression of *fibroblast growth factor 8 (fgf8)* in the anterior neural ridge. In zebrafish, modulations of Fgf8 signaling by RERE were also observed in the context of posterior mesoderm formation, midbrain-hindbrain boundary maintenance, and the development of pharyngeal cartilage and inner ear \[[@r4]; [@r76]\]. The apparently divergent effects of ATN1 and RERE on animal development suggest that their functions are not equivalent. Since ATN1 resembles a truncated form of RERE ([Figure 1](#fig1){ref-type="fig"}), the portion of RERE that is missing from ATN1 could account for their functional differences.

As the *Drosophila* counterpart of RERE, Atro is also crucial for the development of *Drosophila*. Embryos deficient of maternal or both the maternal and zygotic component of *Atro* exhibit severe segmentation defects \[[@r21]; [@r39]; [@r119]\]. Such *Atro* mutant embryos also lack some ventral patterning elements, and often show holes in the ventral cuticle, suggesting that in addition to its better characterized involvement in anterior-posterior patterning, *Atro* also participates in dorsal-ventral axis patterning. In embryos devoid of Atro protein (using a null *Atro* allele), the expression patterns of several segmentation gap genes, such as *hunchback*, *Krüpple* and *knirps (kni)*, are altered \[[@r21]; [@r105]\]. The altered expression of gap genes can partly explain the subsequent abnormal expression of pair-rule genes, such as *fushi-tarazu (ftz)* and *hairy*. However, evidence from experiments using hypomorphic *Atro* alleles reveals that Atro also functions downstream of the gap genes. For example, embryos derived from females carrying hypomorphic *Atro* alleles do not show loss of continuous segments (gap gene phenotype), but, instead, display loss of even-numbered (*ftz*-dependent) *engrailed* stripes \[[@r39]; [@r119]\]. Consistently, the cuticles of such *Atro* mutant embryos also display strong *ftz*-like segmentation defects. Although these *ftz*-phenotypes could result from the loss of the repressive activity of a pair-rule protein Even-skipped (Eve), as suggested in \[[@r119]\], other regulatory pathways that control the expression of *ftz* may be affected by *Atro* mutations as well.

Atro is also involved in other developmental pathways. For example, mutations of *Atro* affect planar polarity in the eyes in a non-autonomous manner \[[@r22]; [@r119]\], and also cause patterning defects in the legs \[[@r21]; [@r106]\]. Atro can antagonize the activity of EGFR (epidermal growth factor receptor) as well \[[@r12]\], since in the *Drosophila* wing, mutation of *Atro* or reduced expression of Atro results in ectopic vein formation \[[@r12]; [@r39]; [@r104]\]. (Note that wing vein formation is known to be initiated by activated EGFR \[[@r55]\]). The possibility that Atro negatively regulates EGFR signaling is further supported by the genetic interactions between Atro and several key genetic components in the EGFR signaling pathways, including *argos*, *rolled*, *pointed*, and *yan* (*anterior open*), in both *Drosophila* wing and eye \[[@r12]\].

The function of Atro has also been connected with microRNA. Steve Cohen's group at Temasek, Singapore, reported recently that *Atro* is a target of miR-8, after they identified four potential *miR-8* binding sites at the 3' untranslated region (3'UTR) of the *Atro* gene \[[@r41]\]. In support of their finding, the leg phenotype displayed by *mir-8* mutants is similar to that caused by the overexpression of Atro \[[@r12]; [@r41]\]. Additionally, reducing Atro activity can rescue the survival rate of these *mir-8* mutant flies \[[@r41]\]. Regulation of *Atro* by miR-8 appears to be a conserved feature, because the same group found that 3'UTR of the *Rere* gene also contains three potential targets of miR-429 and miR-200b, which are the vertebrate counterparts of miR-8. Therefore, a key function of miR-8 and miR-429/miR-200b may be to fine-tune the expression levels of Atro and RERE in *Drosophila* and in vertebrates. Consequently, altered expression of miR-8, -200b, or -429 is expected to affect the developmental pathways that are regulated by Atro or RERE.

Roles in nuclear receptor signaling
===================================

Our lab recently defined Atrophin proteins as corepressors of nuclear receptors through our work with *Drosophila* Tailless (Tll) and vertebrate Tlx \[[@r105]\], which are two closely related nuclear receptors belonging to the 2E subgroup of the nuclear receptor family (NURSA, http://www.nursa.org/). An interaction between Tlx and ATN1 was also reported by Ron Evans' lab at the Salk Institute \[[@r118]\].

Tll is a gap protein involved in specifying terminal cell fate during early embryogenesis \[[@r51]; [@r75]\], and it is also implicated in neurogenesis \[[@r114]\]. In parallel with the roles of Tll in *Drosophila* nervous system development, Tlx participates in regulating vertebrate retinal and forebrain development \[[@r58]; [@r82]; [@r118]\] and in maintaining adult neural stem cells \[[@r86]; [@r94]; [@r117]\]. Both Tll and Tlx have long been known to exert potent transcriptional repression \[[@r31]; [@r71]; [@r72]; [@r116]\] and have been defined as dedicated transcriptional repressors \[[@r60]\]. The underlying molecular mechanisms, however, remained unclear until our discovery of their association with Atrophin proteins.

Our results show that Tll/Tlx-Atrophin interactions are mediated through the ligand binding domain (LBD) of Tll/Tlx and the C-terminal regions of the three Atrophin proteins \[[@r105]\] (regions marked in blue, [Figure 1](#fig1){ref-type="fig"}). In keeping with these observed physical interactions between Tll/Tlx and Atrophin proteins, our *in vivo* studies in *Drosophila* demonstrated that Atro indeed assists Tll in repressing the expression of *kni*, a segmentation gap gene known to be a direct target of Tll \[[@r71]\]. The following data indicate that Atro is involved in the Tll-regulatory pathways: (1) depletion of *Atro* from *Drosophila* embryos leads to derepression of *kni* similar to that in *tll* mutant embryos; (2) mutation of *Atro* in *tll* mutant embryos enhances the *kni* derepression; and (3) Atro is naturally present in a region within the *kni* promoter containing a defined Tll-binding site, as demonstrated by chromatin immunoprecipitation assays.

A recent report reveals that regulation of *kni* by *Atro* also involves another nuclear protein, called Brakeless (Bks, also referred to as Scribbler, Sbb). Mattias Mannervik's group (Stockholm University, Sweden) reported that Atro and Bks/Sbb physically and genetically interact with each other to regulate *kni* expression \[[@r29]\]. This finding resonates with an earlier report from Gerard Campbell's group at the University of Pittsburgh, which showed that *Atro* interacts genetically with *sbb* to repress the expression of several genes, including *thickveins*, *runt*, *aristaless* and *Bar*, in fly imaginal discs \[[@r106]\]. Mannervik's group further demonstrated that a human homolog of Bks/Sbb, zinc finger protein 608 (ZNF608), can also interact with ATN1 directly \[[@r29]\]. Based on this finding, it is possible that ZNF608 and another Bks/Sbb-related protein, ZNF609, may be involved in nuclear receptor signaling in vertebrates as well.

Aside from Tll/Tlx, our data also show that Atrophin proteins interact with additional nuclear receptors. For example, Atrophin proteins bind several members of the NR2F group, including human chicken ovalbumin upstream promoter-transcription factor (COUP-TF) and its *Drosophila* homologue Seven-Up (SVP) \[[@r105]\]. This result was somewhat surprising, because NR2F proteins are also known to interact with SMRT family corepressor proteins \[[@r5]; [@r88]\], including SMRT (silencing mediator of retinoid and thyroid hormone receptors) \[[@r13]\], N-CoR (nuclear receptor corepressor) \[[@r33]\], and *Drosophila* SMRTER (SMRT-related ecdysone receptor interacting factor) \[[@r99]\]. Therefore, certain nuclear receptors, like COUP-TF/SVP, are able to bind two classes of nuclear receptor corepressors, perhaps by means of flexible structural configurations. Whether Atrophin- and SMRT-family proteins bind COUP-TF/SVP in a competitive or a collaborative manner, and whether Atrophin proteins can interact with additional nuclear receptors, are important questions that still wait to be addressed.

Structural and functional domains
=================================

The strong transcriptional repressive activity associated with Atrophin proteins has been reported by numerous laboratories. For example, mutations of *Atro* cause derepression of several segmentation gap genes in *Drosophila* \[[@r21]\]; Atro binds the transcriptional repressor Even-skipped (Eve) and mediates its transcriptional repressive effect \[[@r119]\]; Atro and ATN1 can provide a heterologous Gal4 DNA-binding domain the ability to repress gene transcription in *Drosophila* \[[@r119]\]; and the N-terminal regions of both RERE and Atro mediate strong histone deacetylase (HDAC) activities \[[@r105]\]. The properties associated with each functional domain of the Atrophin proteins described below thus help explain how Atrophin proteins exert potent repression to regulate gene transcription.

As shown in [Figure 1](#fig1){ref-type="fig"}, ATN1 is a smaller protein (1191 aa), compared to RERE (1566 aa) and to Atro (1966 aa) \[[@r21]; [@r43]; [@r61]; [@r112]; [@r119]\]. Unlike ATN1 and Atro, RERE does not contain any long glutamine-repeat tract. There are two regions located in the C-terminus of RERE that are conserved in ATN1 (the percentages of their identical and similar sequences are shown in [Figure 1](#fig1){ref-type="fig"}). Some sequences in the second (the C-terminal) conserved region can also be found in Atro. The functional importance of this conserved region is reflected in its coding of the Atro-box, which is essential for Atrophin proteins to interact with Tll and Tlx \[[@r105]\].

ATN1 resembles a truncated version of RERE because it lacks the entire N-terminal region of RERE that harbors several functional domains such as the BAH (bromo adjacent homology) domain, the ELM2 (EGL-27 and MTA1 homology 2) domain, and the SANT (SWI3/ADA2/N-CoR/TFIII-B) domain, as well as a zinc finger (ZnF) GATA-like motif. Among these domains, only the ELM2 and SANT domains can be found in Atro. The conservation of these two domains in both RERE and Atro implies that they are functionally important. Because BAH domain and the GATA-like motif are unique to RERE, it is anticipated that RERE has additional properties that do not apply to Atro.

The RE-repeats
--------------

One unique feature in the sequences of Atrophin proteins is their coding of dipeptide repeats. The dipeptide consists of either arginine-glutamic acid (RE), lysine-glutamic acid (KE), arginine-aspartic acid (RD), or lysine-aspartic acid (KD). For convenience, and to be consistent with earlier reports, we refer to these dipeptide repeats as RE-repeats. RERE contains three such repeats: one is located at its very N-terminal end and the other two reside in its C-terminal region. ATN1 has two RE-repeats occupying positions similar to those in the C-terminus of RERE. Interestingly, Atro contains only one RE-repeat. The exact functions of such RE-repeats are currently unclear, although it has been suggested that they are involved in mediating the interaction between RERE and ATN1 \[[@r112]\].

The ELM2 domain
---------------

This domain was first described in a *C. elegans* protein, EGL-27 \[[@r30]\], which is a nuclear protein involved in embryonic patterning, cell polarity, cell migration, and vulval development \[[@r30]; [@r90]; [@r91]\]. Based on its sequence, EGL-27 is likely to be an ortholog of Atrophin in the nematode *C. elegans*. Therefore, EGL-27 may be involved in nuclear receptor signaling in *C. elegans*. The ELM2 domain can also be found in many other transcriptional regulators, for example, vertebrate and invertebrate MTA1, 2, 3 (metastasis-associated proteins), CoREST (corepressor of REST), and MIER1 (mesoderm induction early response 1) \[[@r3]; [@r6]; [@r19]\]. The functions of these different nuclear factors have been under intensive investigation. For instance, MTAs are components of the nucleosome remodeling and histone deacetylase (NuRD) complex \[[@r111]; [@r120]\], whose other components include ATP-dependent chromatin remodeling protein Mi-2/CHD4 (chromodomain helicase DNA binding protein 4), HDAC 1/2 (histone deacetylase 1 and 2), MBD (methyl CpG binding protein) 2/3, and histone interacting proteins RbAp48/p46. Elevated expression of MTA proteins has been associated with several metastatic cancers \[[@r6]; [@r52]\]; CoREST is required for REST/NRSF (RE1-silencing transcriptional factor, also called neuron-restrictive silencer factor) to silence the expression of several neural-specific genes \[[@r3]\]; and MIER1 is expressed at a higher level in several breast carcinoma cell lines and breast tumors \[[@r74]\]. Owing to the studies by Ding et al. and our laboratory, one of ELM2's key functions has been demonstrated to be the recruitment of HDAC1/2 \[[@r19]; [@r105]\].

The SANT domain
---------------

This domain is a 50-amino acid-motif that was first reported in 1996. It is present in many factors involved in transcriptional regulation \[[@r1]; [@r8]\]. Sequence and structure analyses indicate that the SANT domain consists of three α-helices \[[@r17]; [@r26]\], and is homologous to the DNA-binding domain (DBD) of c-Myb related proteins. Despite this similarity, no report has shown that the SANT domain can bind DNA. Instead, it codes for diverse functions. For example, (1) a SANT domain of ADA2 and SMRT interacts with histone tails \[[@r7]; [@r115]\]; (2) a SANT domain of SMRT binds to and activates histone deacetylase 3 (HDAC3) \[[@r27]\]; (3) the SANT domain of MIER1 binds Sp1 and interferes with its transcriptional activating activity \[[@r18]\]; (4) a SANT domain enables CoREST to stimulate the histone demethylation activity of LSD1 (lysine specific demethylase 1) \[[@r87]\]; (5) the SANT domain is essential for RERE to form nuclear foci \[[@r105]\]; and (6) the SANT domain of RERE binds G9a \[[@r104]\], which is a major histone H3-lysine 9 methyltransferase \[[@r79]; [@r95]\]. These results suggest that SANT is a versatile domain whose properties may be determined not only by its coding sequence, but also by other regions of the proteins within which it resides. Interestingly, many SANT-domain proteins, including vertebrate and invertebrate MTAs, CoREST, MIER-1, also contain the ELM2 domain. The conjoined conservation of both domains in various transcriptional regulators reveals not only their functional importance, but also their potential connection.

The BAH domain
--------------

This domain was first identified in the chick Polybromo-1 protein, which also contains multiple bromo domains \[[@r62]\]. The human homolog of Polybromo-1, called BAF180, is a component of the SWI/SNF chromatin remodeling complex PBAF (polybromo, BRG-1 associated factors) \[[@r110]\]. The BAH domain is also present in a wide range of proteins, including all three MTA proteins, a trithorax group protein ASH1 (absent, small, or homeotic discs 1), eukaryotic DNA (cytosine-5) methyltransferases, the Orc1 (origin recognition complex 1) proteins, Sir3 (silent information regulator 3), and yeast RSC1/2 (remodeling the structure of chromatin 1/2) \[[@r9]; [@r25]\]. One characterized function of the BAH domain is to mediate the interaction between Orc1 and Sir1, which plays a key role in establishing the silent chromatin structure at the cryptic mating-type loci HMR and HML in yeast \[[@r96]\]. The same group (Rolf Sternglanz, Stony Brook University) also reported that the BAH domain is crucial for the function of Sir3 in transcriptional silencing \[[@r16]\]. Recently, the BAH domain of yeast Sir3 was reported to bind to nucleosome and histone tails \[[@r68]\].

The information discussed above suggests that Atrophin proteins, through their multiple functional domains, can act as scaffolds for recruiting various transcriptional cofactors, which, in turn, enable Atrophin proteins to effectively repress transcription. This view is supported by our recent finding that the ELM2 and SANT domains of RERE can recruit multiple proteins in human cells \[[@r104]\]. This finding also resonates with two earlier reports that MTA proteins and CoREST (which are ELM2-SANT domain proteins) are components of large protein complexes whose properties range from chromatin remodeling and histone deacetylation to transcriptional repression \[[@r6]; [@r52]; [@r111]; [@r120]\]. Since the transcriptional properties of the Atrophin proteins depend on their associated factors, these factors create pathways through which different developmental or environmental cues can modify the properties of Atrophin proteins in a context-dependent manner ([Figure 2](#fig2){ref-type="fig"}).

Connections with histone modification
=====================================

Histone tails are subject to different covalent modifications, including acetylation, methylation, phosphorylation and ubiquitination \[[@r93]\]. A large body of evidence suggests that controlling the interplay among such modifications is a strategy used by transcription factors or cofactors to regulate gene transcription \[[@r121]\]. Considerable evidence has already shown that histone deacetylation is responsible for creating specific chromatin structures that favor transcriptional repression. Another major histone modification implicated in transcriptional repression is histone lysine methylation, with methylation of histone H3 lysine 9 (H3-K9) being an important marker of heterochromatin and silenced euchromatin \[[@r36]; [@r78]\].

Our recent data indicate that Atrophin proteins bring about transcriptional repression by drawing on both histone deacetylation and histone H3-K9 methylation. As described above, RERE, via its ELM2 domain, recruits HDAC1 and HDAC2 \[[@r105]\] and, through its SANT domain, recruits the histone H3-K9 methyltransferase G9a \[[@r104]\]. In studying the properties of the ELM2 and SANT domains of RERE, we found that, by coordinating the action of HDAC1/2 and G9a, these two domains of RERE catalyze sequential molecular events that first cause the deacetylation of H3-K9 and then allow this deacetylated residue to be methylated by G9a \[[@r104]\]. As a result of these modifications of H3-K9, chromatin structures at the regions where RERE binds become compact and favor gene silencing (see the model shown in [Figure 2](#fig2){ref-type="fig"}). This mode of action may also apply to other transcriptional regulators containing the ELM2 and SANT domains, since our data additionally show that all three MTA proteins and MIER1 not only interact with HDAC1/2, but also bind G9a \[[@r104]\].

Connections with EGFR signaling
===============================

The Atrophin-HDAC1/2-G9a complex is also linked to the EGFR signaling pathway in *Drosophila* \[[@r104]\]. As mentioned earlier, wing vein formation is initiated by the activated EGFR in *Drosophila* \[[@r55]\]. In keeping with the report that Atro acts as a negative factor in the EGFR signaling pathway \[[@r12]\], mutation of *Atro* or reduced expression of Atro (using the double-stranded RNA method) results in ectopic vein formation in the intervein regions \[[@r12]; [@r39]; [@r104]\]. This observed mutant *Atro*-mediated ectopic wing vein phenotype is enhanced when *G9a* or *Rpd3* (the fly HDAC1/2) is also mutated \[[@r104]\]. These genetic data indicate that Atro, dG9a and Rpd3 act together to repress wing vein formation, perhaps by antagonizing the activities of EGFR. Strong genetic interaction among *Atro*, *dG9a* and *Rpd3* also takes place in other tissues. For example, melanotic masses appear in the *Drosophila* head when both *Atro* and *dG9a* or *Rpd3* are removed or mutated. We surmise that the formation of these melanotic masses is a result of accumulated hemocytes. Whether this phenotype involves a hyperactive EGFR signaling pathway remains to be investigated.

Atrophin appears to be involved in growth-factor signaling pathways in other species as well. Julie Ahringer's group (University of Cambridge, UK) has shown that EGL-27, the worm Atrophin-like protein, acts to inhibit vulval development in *C. elegans* by antagonizing Ras signaling \[[@r90]\], which takes place downstream of growth-factor signaling pathways. Therefore, negative regulation of the EGFR-Ras pathway may be a conserved property shared by Atrophin proteins and their associating factors. Since hyperactive EGFR and Ras are associated with various cancers, their oncogenic effects may result from their interference with the transcriptional repressive properties of the Atrophin-HDAC1/2-G9a protein complex.

Janus-faced transcriptional properties, and beyond transcription
================================================================

Owing to their relationship with transcriptional repressors and HDACs, Atrophin proteins have been viewed primarily as dedicated corepressors. However, considerable evidence suggests that Atro can regulate gene transcription in a positive manner as well. For example, Ian Duncan's group (Washington University, St. Louis) reported that *ftz* expression is reduced in *Drosophila* embryos mutant of *Atro* \[[@r39]\]. In the same report, they provided additional evidence suggesting that Atro is a member of the trithorax group (trxG) proteins, which are known to regulate the expression of homeotic genes positively. Their evidence includes: (1) mutations of *Atro* enhance the loss-of-function phenotypes of antennapedia complex and bithorax complex genes; (2) the phenotypes caused by the mutations of two *trxG* genes, *brahma* and *trithorax*, are enhanced by mutations of *Atro*; and (3) the leg phenotype caused by mutations in *Polycomb-like*, a *polycomb group* (*PcG*) gene, is suppressed by mutations of *Atro*. (Note that *PcG* genes have opposite effects from *trxG* genes on regulating the expression of homeotic genes.)

In many respects, the observed behavior of Atro resembles that of Osa, as also suggested by Ian Duncan's group. Osa is a trxG group protein known to associate with the Brahma chromatin remodeling complex \[[@r14]; [@r101]\]. While the functions of Osa have been associated primarily with transcriptional activation, it has been linked with transcriptional repression as well. For example, Jessica Treisman's group (Skirball Institute, New York University) showed that several *wingless* target genes are repressed by Osa \[[@r15]\]. Therefore, both Atro and Osa may be bifunctional transcriptional regulators whose transcriptional properties (either positive or negative) can be influenced by other factors or by posttranslational modifications. This idea is further supported by the finding that the C-terminal region of RERE contains a domain that can activate gene transcription through its association with the transcriptional coactivator p300 \[[@r85]\]. Since our recent data indicate that RERE is subject to protein cleavage \[[@r104]\], the cleavage event---which allows the C-terminal transcriptional activating module to be separated from the N-terminal transcriptional repressive module---could be responsible for converting RERE from a transcriptional repressive form to a transcriptional activating form. My laboratory is currently investigating this possibility.

Although Atro has been investigated predominantly as a nuclear protein, Helen McNeill's group (Samuel Lunenfeld Research Institute, Mt. Sinai Hospital, Canada) has reported that Atro physically interacts with the cytoplasmic domain of the atypical cadherin Fat *in vitro* \[[@r22]\], and that Atro collaborates with Fat to control planar polarity in the *Drosophila* eye. These results suggest that Atro might have non-nuclear functions as well. Furthermore, ATN1 localizes predominantly to the cytoplasm of neuronal cells \[[@r42]\], and can interact with several proteins with functions outside the realm of transcriptional regulation. Several ATN1-interacting proteins (AIPs) isolated from yeast two hybrid screens \[[@r108]\] are known to function in the cytoplasm. For example, AIP1 is a membrane-associated guanylate kinase family protein that interacts with the tumor suppressor PTEN and enhances its ability to suppress Akt activation \[[@r109]\]. AIP4 is an ubiquitin E3 ligase, which regulates the degradation of the human enhancer of filamentation 1 (HEF1) in TGF-β (transforming growth factor β) signaling pathways \[[@r23]\]. ATN1 may also function in an insulin-related signaling pathway, since ATN1 can bind the SH3 (Src homology 3) domain of a human homologue of the insulin receptor tyrosine kinase substrate protein of 53kD (IRSp53) in the cytoplasm \[[@r67]\].

A comparison between the Atrophin- and SMRT-family proteins
===========================================================

In many respects, the functional properties discovered for Atrophin family proteins resemble those found for SMRT family proteins, which are, by far, the best characterized nuclear receptor corepressors. Aside from their functional resemblance, these two groups of nuclear receptor corepressors also exhibit their own unique features. A comparison of their known properties is described below and summarized in [Figure 3](#fig3){ref-type="fig"}.

\(1\) Both families\' proteins are conserved. Each includes a *Drosophila* protein (Atro and SMRTER), and two vertebrate paralogues (ATN1, RERE and SMRT, N-CoR) \[[@r13]; [@r21]; [@r33]; [@r43]; [@r61]; [@r99]; [@r112]; [@r119]\]. All of these proteins contain RE-repeats and all, except ATN1, also contain one or two SANT domains. Moreover, all proteins in both groups, except RERE, contain at least one glutamine-tract.

\(2\) Both families\' proteins interact with nuclear receptors in a selective way. SMRT, N-CoR and SMRTER preferentially bind nuclear receptors, such as retinoic acid receptor (RAR), thyroid hormone receptor (TR), peroxisome proliferator-activated receptor (PPAR) and ecdysone receptor (EcR) \[[@r37]; [@r47]; [@r77]; [@r98]\], but not Tll and Tlx \[[@r105]\]. Atrophin proteins, in contrast, interact strongly with Tll and Tlx, but barely with RAR, TR, PPAR or EcR \[[@r105]\]. Their differential affinity towards different groups of nuclear receptors may result from the different structural motifs these two groups of proteins use to interact with nuclear receptors. For example, Mitch Lazar's group (University of Pennsylvania) identified a CoRNR box (or L/I-X-X-I/V-I motif) in both SMRT and N-CoR that enables both proteins to interact with nuclear receptors \[[@r34]\]. We identified a stretch of highly conserved amino acids, termed the Atro-box ([Figure 1](#fig1){ref-type="fig"}), in all Atrophin proteins that are essential for them to bind Tll and Tlx \[[@r105]\].

\(3\) Both families\' proteins interact with HDACs, also in a selective way. SMRT and N-CoR bind HDAC3 strongly \[[@r28]; [@r48]\], while their associations with HDAC1 and HDAC2 are relatively weak \[[@r105]\]. Atrophin proteins show the opposite preferences, with Atro and RERE strongly interacting with HDAC1 and HDAC2, but barely with HDAC3 \[[@r105]\]. Considering that SMRT proteins can also bind to type II HDACs, such as HDAC 4, 5, and 7 \[[@r35]; [@r40]\], it is possible that Atrophin proteins may associate selectively with type II HDACs as well.

\(4\) Atrophin proteins, except ATN1, associate with HMTases such as G9a \[[@r104]\]. Although direct interactions between SMRT family proteins and HMTase have not been reported, data from our laboratory indicate that transcriptional repression mediated by SMRT family proteins also involves HMTases. This finding, together with the results described above, suggests that recruiting both HDACs and HMTases is an important and shared strategy used by nuclear receptor corepressors to repress gene transcription.

Implications for diseases
=========================

DRPLA
-----

Polyglutamine expansion within human ATN1 causes DRPLA, which is also known as Haw River Syndrome and Naito-Oyanagi disease. DRPLA is one of the nine late-onset polyglutamine neurodegenerative diseases, which also include Huntington's disease, spinobulbar muscular atrophy, and spinal cerebellar ataxias 1, 2, 3, 6, 7, and 17 \[[@r122]\]. The clinical features of DRPLA include dementia, choreoathetosis, myoclonus epilepsy, and ataxia \[[@r100]\]. Like most polyglutamine diseases, the pathogenic mechanism underlying DRPLA remains elusive. It had been speculated that glutamine-repeat expansion in ATN1 compromises its own function. This view, however, has been challenged by a recent report that *Atn1^-/-^* mice show no neurological defects or other phenotype \[[@r85]\]. Therefore, the dominant negative effect caused by the glutamine-repeat expanded form of ATN1 is likely mediated through pathways other than a simple loss of function of ATN1.

Several models have been proposed to explain the neurotoxicity caused by mutant ATN1, including the formation of nuclear aggregates or inclusions, which is a hallmark of polyglutamine diseases \[[@r81]\], protein cleavage of ATN1 \[[@r20]; [@r64]; [@r83]\], and phosphorylation of ATN1 \[[@r66]\]. Thus far, the exact roles of such modifications of ATN1 in the pathogenesis of DRPLA have not been firmly established. With regard to protein cleavage, a caspase-3 cleavage site was mapped to the Asp109 of ATN1; expressing this cleaved form of ATN1 causes cytotoxicity in cultured cells \[[@r20]\]. Although the *in vivo* relevance of this cleaved form of ATN1 to DRPLA development is still unclear, the fact that ATN1 is involved in transcriptional regulation suggests that this cleavage event might affect its transcriptional (and perhaps toxic) properties.

Transcriptional abnormality has recently emerged as a potential pathogenic mechanism responsible for many polyglutamine diseases \[[@r80]\]. The glutamine-repeat expanded form of ATN1 interacts strongly with TAF~II~130 and can suppress CREB-dependent transcriptional activation \[[@r89]\]. CBP is sequestered into nuclear inclusions found in DRPLA postmortem brain tissue, and the N-terminal truncation of the expanded ATN1 can inhibit CBP-mediated transcription \[[@r65]\]. Correlatively, a DRPLA transgenic mouse model expressing ATN1 with 118Q exhibits hypoacetylation of histone H3 in brain tissues, whereas the administration of sodium butyrate, an HDAC inhibitor, ameliorates the neurodegenerative phenotypes of such mice \[[@r113]\]. These observations strongly suggest that abnormal gene repression is a contributing factor for the development of DRPLA.

Although sequestration of CBP into ATN1-mediated nuclear inclusions may partly account for mutant ATN1-mediated changes in gene expression profile and neurotoxicity, other mechanisms may also be involved. With our recent identification of Atrophin proteins as nuclear receptor corepressors, one plausible explanation for the development of DRPLA is that nuclear receptor signaling pathways are perturbed. It is noteworthy that ATN1\'s interacting partners, such as Tlx and COUP-TF, are expressed and function in the nervous system \[[@r58]; [@r73]; [@r82]; [@r86]; [@r97]; [@r116]\]. The pathogenesis of DRPLA might also involve RERE, considering that RERE can dimerize with ATN1 and that RERE-ATN1 interaction is enhanced when ATN1's glutamine-repeat is expanded \[[@r112]\]. In fact, the latter model is supported by the effects caused by ATN1 in *Drosophila*: expressing a pathological form of ATN1 in *Drosophila* generates a phenotype similar to that caused by mutations of *Atro* \[[@r12]\].

We here propose several mechanisms that might explain how ATN1 affects Atro-dependent pathways in *Drosophila*: (1) The functions of Atro may be compromised upon its association with the insoluble form of mutant ATN1; (2) stabilized mutant ATN1 may compete with Atro to bind common transcriptional cofactors; and (3) a stabilized mutant ATN1, which lacks intrinsic HDAC and HMTase activities \[[@r104]; [@r105]\], might gain both chromatin-modifying activities upon its association with Atro. Any of these hypothesized mechanisms would affect the transcriptional properties of Atro in *Drosophila*. With the observed effects of ATN1 in *Drosophila* in mind, one tempting theory for the mechanism of DRPLA in vertebrates is that the functions of RERE are affected by mutant ATN1. If so, we predict that the phenotypes displayed by DRPLA mice will be enhanced when one allele of the *Rere* gene is removed or mutated.

Cancers
-------

The gene for *Rere* is located in the distal region of chromosome 1p, where frequent structural rearrangements have been reported in association with several human malignancies \[[@r84]\]. For example, the neuroblastoma cell line NGP contains a reciprocal chromosomal translocation/duplication t(1;15)(p36.2;q24), Dp(1)(p36.2-p36.3) \[[@r11]\]. It has been reported that the *Rere* gene unit is disrupted in NGP \[[@r2]\]. Additionally, the expression of *Rere* transcripts is altered in many neuroblastoma cell lines \[[@r102]\]. In cultured cells, transiently overexpressed RERE colocalizes with BAX, a proapoptotic protein, and enhances caspase-dependent apoptosis \[[@r102]\]. The latter result implies that mutation of *Rere* may prevent damaged cells from undergoing cell death, thus leading to cancer development.

ATN1 has also been shown to interact with ETO/MTG8 \[[@r107]\], a transcriptional coregulator whose fusion with RUNX1 causes the most common form of t(8;21) acute myeloid leukemia (AML) \[[@r44]; [@r59]; [@r63]\]. Interestingly, ETO/MTG8 has been shown previously to be an associating factor of SMRT, N-CoR, Sin3A and HDACs \[[@r24]; [@r50]; [@r103]\]. The association between ETO/MTG8 and various transcriptional corepressors suggests that aberrant transcriptional repression imposed on RUNX1-regulatory pathways by the ETO-RUNX1 fusion protein could be an underlying reason for the pathogenesis of AML1. If so, reducing the transcriptional repressive activities of either or both Atrophin-family and SMRT-family proteins could provide a feasible therapeutic strategy for treating AML1.

Therapeutic implications
------------------------

Abnormal expression levels of MTAs and MIER1 have been linked to different forms of metastatic tumors or different carcinoma cell lines \[[@r6]; [@r19]; [@r46]; [@r102]\]. Since our recent work shows that these proteins are associated with HDAC1/2 and G9a \[[@r104]\], we suspect that alteration of their expression levels may cause aberrant transcriptional repression and, consequently, may result in the development or progression of cancers. Recently, HDAC inhibitors \[[@r54]\] have been tested as promising agents in treating blood-borne cancers, and also in treating polyglutamine diseases \[[@r10]; [@r32]; [@r56]; [@r57]; [@r92]; [@r113]\]. Since specific G9a inhibitors have also been recently reported by Thomas Jenuwein's lab at the Vienna Biocenter, Austria \[[@r45]\], our study raises the possibility that these G9a inhibitors might also be used, alone or together with the current FDA-approved HDAC inhibitors, for treating cancers and neurological diseases involving Atrophin, MTAs, CoREST or MIER1 ([Figure 2](#fig2){ref-type="fig"}).

Concluding remarks
==================

Rapid progress during the past few years has produced a much better understanding of the Atrophin protein family\'s molecular functions. The exciting discovery that Atrophin proteins are nuclear receptor corepressors enables us to look at these proteins from a nuclear receptor signaling perspective. Our efforts make it clear now that Atrophin proteins employ mechanisms, such as histone deacetylation and histone lysine methylation, to repress gene transcription. It is only a matter of time before more nuclear receptors, transcriptional factors, and histone/chromatin-modifying factors are identified that associate with Atrophin proteins. In-depth study of Atrophin proteins and their functions in connection with nuclear receptor, EGFR, and chromatin-modifying factors will not only lead to a better understanding of their roles in animal development and in human diseases, but will also pave the way for the identification of potential therapeutic targets for treating various human diseases.
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